Skip to main content

Table 1 Patient characteristics and further treatment of local or distant tumour relapse

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

 

standard group (IMRT only)

experimental group (IMRT + C12)

number of patients

37

58

deceased

30 (81%)

26 (45%)

mean OS (months)

68.4

78.3

local relapse

23 (62%)

29 (50%)

 surgery

4 (17%)

17 (59%)

 re-RT

14 (61%)

13 (45%)

 re-RT as C12

1 (8%)

8 (62%)

 chemotherapy

1 (4%)

 

distant metastases

16 (43%)

22 (38%)

 chemotherapy

16 (100%)

21 (95%)

 palliative RT

5 (31%)

8 (36%)